Company: SONM
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001493152-25-016055
Chunk: 12

Company: SONIM TECHNOLOGIES INC
Filing Date: 2025-09-29
Form: S-1
Chunk 12
---
Conflicts of Interest).”                                                                                     |
| Listing and trading symbol                       |     | Shares of our common                                                                                                                    
 stock trade on Nasdaq under the symbol “SONM.”                                                                                          |
| Risk                                             
 factors                                          |     | Any                                                                                                                                     
 investment in the securities offered hereby is speculative and involves a high degree of risk.                                          
 You should carefully read and consider the information set forth under the heading “Risk Factors”                                       
 and all other information set forth therein as well as under headings “Risk Factors” in the documents incorporated                      
 by reference to this prospectus.                                                                                                        |

The number of shares of our Common Stock to be outstanding immediately after this offering is based on 10,338,905 shares of our Common Stock outstanding as of June 30, 2025, and excludes, as of such date:

● 900,000 shares of common stock issuable upon the exercise of outstanding warrants;

● 675,779 shares of common stock issuable upon the exercise of outstanding options; and

● 26,957 shares of common stock that remain available for future equity grants under the Sonim Technologies, Inc. 2019 Equity Incentive Plan, as amended (the “EIP”).

| 7 |

<div align='center'>Risk Factors</div>

You should carefully consider the risks and uncertainties described below and the other information in this prospectus before making an investment in our common stock. Our business, financial condition, results ofoperations , or prospects could be materially and adversely affected if any of these risks occur, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See “ Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below.

Risks Related to the Facility

It is not possible to predict the actual number of shares of our Common Stock, if any, we will sell under the Purchase Agreement to Chardan, or the actual gross proceeds resulting from those sales or the dilution to you from those sales.

On September 29, 2025, we entered into the Purchase Agreement with Chardan, pursuant to which we may sell to Chardan up to $500.0 million of shares of our Common Stock (the “Total Commitment”), upon the terms and subject to the conditions and limitations set forth in the Purchase